| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.29 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
775,593 |
1,206,168 |
1,357,304 |
2,009,275 |
| Total Sell Value |
$6,587,745 |
$9,420,070 |
$9,994,774 |
$10,729,161 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
37 |
60 |
105 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rosenbaum David P. |
Chief Development Officer |
• – – |
2022-02-22 |
4 |
S |
$0.67 |
$403 |
I/I |
(601) |
105,026 |
|
13% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2022-02-22 |
4 |
S |
$0.67 |
$1,174 |
D/D |
(1,752) |
349,409 |
|
13% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2022-02-22 |
4 |
S |
$0.67 |
$1,206 |
D/D |
(1,800) |
333,887 |
|
13% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2022-02-22 |
4 |
S |
$0.67 |
$1,024 |
D/D |
(1,528) |
316,430 |
|
13% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2022-02-22 |
4 |
S |
$0.67 |
$2,278 |
D/D |
(3,400) |
333,938 |
|
13% |
|
| Blanks Robert |
See Remarks |
• – – |
2022-02-22 |
4 |
S |
$0.67 |
$1,174 |
D/D |
(1,752) |
399,116 |
|
13% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
141,000 |
338,031 |
|
- |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
42,000 |
335,687 |
|
- |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
42,000 |
317,958 |
|
- |
|
| Blanks Robert |
See Remarks |
• – – |
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
400,868 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2022-01-06 |
4 |
A |
$0.00 |
$0 |
I/I |
15,000 |
105,627 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
351,161 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
781,803 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2021-12-15 |
4 |
S |
$1.14 |
$1,384,696 |
I/I |
(1,211,352) |
2,258,850 |
|
27% |
|
| Baskett Forest |
10% Owner |
– – • |
2021-12-15 |
4 |
S |
$1.14 |
$1,384,696 |
I/I |
(1,211,352) |
2,258,850 |
|
27% |
|
| Sandell Scott D |
10% Owner |
– – • |
2021-12-14 |
4 |
S |
$1.24 |
$1,245,014 |
I/I |
(1,000,735) |
2,582,017 |
|
27% |
|
| Baskett Forest |
10% Owner |
– – • |
2021-12-14 |
4 |
S |
$1.24 |
$1,245,014 |
I/I |
(1,000,735) |
2,582,017 |
|
27% |
|
| Sandell Scott D |
10% Owner |
– – • |
2021-12-09 |
4 |
S |
$1.51 |
$1,012,861 |
I/I |
(669,483) |
2,798,066 |
|
53% |
|
| Baskett Forest |
10% Owner |
– – • |
2021-12-09 |
4 |
S |
$1.51 |
$1,012,861 |
I/I |
(669,483) |
2,798,066 |
|
53% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2021-11-22 |
4 |
S |
$0.99 |
$638 |
D/D |
(643) |
197,030 |
|
-19% |
|
| Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-11-22 |
4 |
AS |
$0.98 |
$5,629 |
D/D |
(5,754) |
119,483 |
|
19% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-11-22 |
4 |
S |
$0.99 |
$182 |
I/I |
(184) |
90,627 |
|
-19% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-11-22 |
4 |
S |
$0.99 |
$638 |
D/D |
(643) |
311,161 |
|
-19% |
|
| Raab Michael |
President & CEO |
• • – |
2021-11-22 |
4 |
S |
$0.99 |
$2,586 |
D/D |
(2,607) |
631,803 |
|
-19% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2021-11-22 |
4 |
S |
$0.99 |
$533 |
D/D |
(537) |
275,958 |
|
-19% |
|
557 Records found
|
|
Page 7 of 23 |
|
|
0.17 (2.57%) 
